Download PDF
TumorDiagnostik & Therapie 2007; 28(2): 81-86
DOI: 10.1055/s-2007-963103
Thieme Onkologie aktuell

© Georg Thieme Verlag KG Stuttgart · New York

Hormontherapie des Prostatakarzinoms - Übersicht und aktueller Stand

Hormonal treatment of cancer of the prostate: review and present statusR. Ganzer1 , W. F. Wieland1 , T. Bach2 , W. Rößler1 , A. Blana1
  • 1Klinik und Poliklinik für Urologie, Universität Regensburg, Krankenhaus St Josef
  • 2Asklepios Klinik Barmbek, Urologische Abteilung
Further Information

Publication History

Publication Date:
16 April 2007 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Das Prostatakarzinom (PC) ist in der westlichen Welt der häufigste bösartige Tumor des Mannes. Durch die Einführung des PSA-Screenings wird das es zunehmend in potenziell kurablen Tumorstadien diagnostiziert. Dennoch kommt es nach kurativer Therapie innerhalb von 15 Jahren in bis zu 50 % zu einem erneuten Anstieg des PSA-Wertes und im Median nach weiteren 8 Jahren in 34 % zu einer Metastasenbildung. Beim systemischen Rezidiv ist die Hormontherapie die wichtigste palliative Maßnahme. Sie wird ebenfalls als Primärtherapie und in Kombination mit anderen Therapieformen eingesetzt. Die verschiedenen Methoden der Kastration (chirurgisch, medikamentös) sind vom Gesamtüberleben her vergleichbar. Die heutzutage für die medikamentöse Kastration eingesetzten LH-RH-Agonisten haben typische Nebenwirkungen in Form von Impotenz (69 %), Hitzewallungen (56,5 %), Gynäkomastie (24,9 %) und Osteoporose. Initial führen LH RH-Agonisten zu einem passageren Serum-Testosteronanstieg (Flare-Phänomen). Dies kann durch LH-RH-Antagonisten vermieden werden, die in Europa noch nicht zugelassen ist. Eine weitere Medikamentengruppe sind die Antiandrogene, die ein günstigeres Nebenwirkungsprofil als die Formen der Kastration besitzen. Das Antiandrogen Bicalutamid führt beim lokal fortgeschrittenen PC, adjuvant zur Radiatio verabreicht, zu einer Überlebensverlängerung, nicht aber bei der Gabe nach radikaler Prostatektomie oder bei Versagen einer „Watchful-waiting”-Strategie. Beim metastasierten PC sind Antiandrogene der Kastration im Gesamtüberleben statistisch signifikant unterlegen. Die Bedeutung der maximalen Androgenblockade (Kombination aus Kastration und Antiandrogen) wird anhaltend kontrovers diskutiert. Sie bietet beim metastasierten PC einen geringen Überlebensvorteil von wenigen Monaten bei deutlicher Zunahme der Nebenwirkungen.

Summary

Prostatic cancer (PC) heads the list of malignant tumors in the male. Resulting from the introduction of prostatic-specific antigen (PSA) screening there has been a shift towards potentially curable tumor stages. However, after curative treatment a rise in PSA has been noted in up to 50 % of cases within 15 years. Metastases are then reported in up to 34 % within the subsequent eight years. Hormonal therapy represents the most important palliative measure in metastatic PC and is also used in primary, adjuvant and neo-adjuvant hormonal treatment. The different methods of castration (orchidectomy, medical castration) are equivalent in respect of overall survival. The side effects of agonists of luteinizing-hormone-releasing hormone (LHRH) are impotence (69 %), hot flushes (56.5 %), gynecomastia (24.9 %) and osteoporosis and may initially cause a transitory increase in serum testosterone (flare phenomenon). This can be counteracted by an LHRH antagonist (not available in Europe). Anti-androgens do not lead to testosterone suppression and have a more favorable profile of side effects. Bicalutamide significantly improves overall survival rate in patients receiving radiotherapy. However, overall survival rate is not improved in patients after radical prostatectomy or under watchful waiting. Bicalutamide alone is less efficacious than castration in patients with metastases. The use of maximal androgen blockade (combination of castration and anti-androgen) remains controversial. It seems to produce a modest overall and cancer-specific increase in survival rate but is associated with increased adverse events and a reduced quality of life.

Schlüsselwörter

Prostatakarzinom - Hormontherapie - Kastration - maximale Androgenblockade - Flare - Phänomen

Key words

prostate cancer - hormone therapy - castration - maximal androgen blockade - flare phenomenon

Literatur

  • 1 Bolla M, Collette L, Blank L. et al . Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.  Lancet. 2002;  360 103-106
    CrossrefPubMedGoogle Scholar
  • 2 Bubley G J. Is the flare phenomenon clinically significant?.  Urology. 2001;  58 5-9
    PubMedGoogle Scholar
  • 3 Byar D P, Corle D K. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies.  NCI Monogr. 1988;  7 165-170
    PubMedGoogle Scholar
  • 4 Catalona W J, Smith D S, Ratliff T L. et al . Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.  N Engl J Med. 1991;  324 1156-1161
    CrossrefPubMedGoogle Scholar
  • 5 Culig Z, Hobisch A, Bartsch G. et al . Androgen receptor - an update of mechanisms of action in prostate cancer.  Urol Res. 2000;  28 211-219
    CrossrefPubMedGoogle Scholar
  • 6 Denis L J, Carnelro de Moura J L, Bono A. et al . Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853): EORTC GU Group and EORTC Data Center.  Urology. 1993;  42 119-129
    CrossrefPubMedGoogle Scholar
  • 7 Eisenberger M A, Blumenstein B A, Crawford E D. et al . Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.  N Engl J Med. 1998;  339 1036-1042
    CrossrefPubMedGoogle Scholar
  • 8 Grossfeld G D, Chang J J, Broering J M. et al . Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database.  J Urol. 2001;  165 851-856
    CrossrefPubMedGoogle Scholar
  • 9 Huggins C B, Hodges C V. Studies on prostate cancer: The effects of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.  Cancer Res. 1941;  1 293-297
    PubMedGoogle Scholar
  • 10 Hunter J. The works of John Hunter F. R. S. With Notes. London: Longman Edited by J. F. Palmer 1837
    Google Scholar
  • 11 Iversen P. Quality of life issues relating to endocrine treatment options.  Eur Urol. 1999;  (Suppl 2) 36 20-26
    CrossrefPubMedGoogle Scholar
  • 12 Iversen P, Tyrrell C J, Kaisary A V. et al . Casodex (bicalutamide) 150 mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.  Urology. 1998;  51 389-396
    CrossrefPubMedGoogle Scholar
  • 13 Iversen P, Tyrrell C J, Kaisary A V. et al . Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.  J Urol. 2000;  164 1579-1582
    CrossrefPubMedGoogle Scholar
  • 14 Klotz L, McNeill I, Fleshner N. A phase 1 - 2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma.  J Urol. 1999;  161 169-172
    CrossrefPubMedGoogle Scholar
  • 15 Krebs in Deutschland. 5. überarbeitete, aktualisierte Ausgabe Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. und das RKI. Saarbrücken 2006
    Google Scholar
  • 16 Mc Ieod D G, Iversen P, See W A. et al . Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.  BJU Int. 2006;  97 247-254
    CrossrefPubMedGoogle Scholar
  • 17 Miyamoto H, Yeh S, Lardy H. et al . Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells.  Proc Natl Acad Sci U S A. 1998;  95 11083-11088
    CrossrefPubMedGoogle Scholar
  • 18 Moffat L E. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer.  Eur Urol. 1990;  18 (Suppl 3) 26-27
    PubMedGoogle Scholar
  • 19 Nyman C R, Andersen J T, Lodding P. et al . The patient’s choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy.  BJU Int. 2005;  96 1014-1018
    CrossrefPubMedGoogle Scholar
  • 20 Paquette E L, Sun L, Paquette L R. et al . Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing.  Urology. 2002;  60 756-759
    CrossrefPubMedGoogle Scholar
  • 21 Pelikan E. Gerichtlich-medicinische Untersuchungen uber Das Skopzenthum in Russland, nebst historischen Notizen. Giessen: Ricker 1876
    Google Scholar
  • 22 Potosky A L, Knopf K, Clegg L X. et al . Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study.  J Clin Oncol. 2001;  19 3750-3757
    PubMedGoogle Scholar
  • 23 Pound C R, Partin A W, Eisenberger M A. et al . Natural history of progression after PSA elevation following radical prostatectomy.  JAMA. 1999;  281 1591-1597
    CrossrefPubMedGoogle Scholar
  • 24 Prostate Cancer Trialists’ Collaborative Group . Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials.  Lancet. 2000;  355 1491-1498
    CrossrefPubMedGoogle Scholar
  • 25 Radlmaier A, Bormacher K, Neumann F. Hot flushes: mechanism and prevention.  Prog Clin Biol Res. 1990;  359 131-140
    PubMedGoogle Scholar
  • 26 Riba L W. Subcapsular castration for carcinoma of prostate.  J Urol. 1942;  48 384-387
    PubMedGoogle Scholar
  • 27 Rohde V, Wellmann A, Fogt F. et al . Economical data and advanced prostate carcinoma: do we need new guidelines for decision making?.  Oncol Rep. 2002;  9 1185-1188
    PubMedGoogle Scholar
  • 28 Scherr D S, Pitts W R. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.  J Urol. 2003;  170 1703-1708
    CrossrefPubMedGoogle Scholar
  • 29 Schroder F H, Collette L, Reijke T M. et al . Prostate cancer treated by anti - androgens? is sexual function preserved: EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer.  Br J Cancer. 2000;  82 283-290
    CrossrefPubMedGoogle Scholar
  • 30 Seidenfeld de J, Samson D J, Hasselblad V. et al . Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta - analysis.  Ann Intern Med. 2000;  132 566-577
    PubMedGoogle Scholar
  • 31 The Veterans Administration Co-operative Urological Research Group . Treatment and survival of patients with cancer of the prostate.  Surg Gynecol Obstet. 1967;  124 1011-1017
    PubMedGoogle Scholar
  • 32 Trachtenberg J, Gittleman M, Steidle C. et al . A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer.  J Urol. 2002;  167 1670-1674
    CrossrefPubMedGoogle Scholar
  • 33 Tsai M J, O’Malley B W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members.  Annu Rev Biochem. 1994;  63 451-486
    CrossrefPubMedGoogle Scholar
  • 34 Tyrrell C J, Kaisary A V, Iversen P. et al . A randomised comparison of ‚Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer.  Eur Urol. 1998;  33 447-456
    CrossrefPubMedGoogle Scholar
  • 35 Wang M C, Valenzuela L A, Murphy G P. et al . Purification of a human prostate specific antigen.  Invest Urol. 1979;  17 159-163
    PubMedGoogle Scholar
  • 36 Weckermann D, Harzmann R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues.  Eur Urol. 2004;  46 279-283
    CrossrefPubMedGoogle Scholar
  • 37 White W J. Surgical of the hypertrophied prostate.  Ann Surg. 1893;  17 70-75
    PubMedGoogle Scholar
  • 38 Widmark A, Fossa S D, Lundmo P. et al . Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3.  Urology. 2003;  61 145-151
    CrossrefPubMedGoogle Scholar
  • 39 Wirth M P, See W A, Mcleod D G. et al . Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years.  J Urol. 2004;  172 1865-1870
    CrossrefPubMedGoogle Scholar
  • 40 Zhang X Z, Donovan M P, Williams B T. et al . Comparison of subcapsular and total orchiectomy for treatment of metastatic prostate cancer.  Urology. 1996;  47 402-404
    CrossrefPubMedGoogle Scholar

Dr. med. Roman Ganzer

Klinik und Poliklinik für Urologie, Universität Regensburg, Krankenhaus St. Josef

Landshuter Straße 65

93053 Regensburg

Phone: 09 41/7 82 35 33

Fax: 09 41/7 82 35 15

Email: roman.ganzer@gmx.de

      >